<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02015416</url>
  </required_header>
  <id_info>
    <org_study_id>IDC-G305-2013-001</org_study_id>
    <nct_id>NCT02015416</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immune Design</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical&#xD;
      safety and immune response of IDC-G305 when injected intramuscularly in patients with&#xD;
      unresectable or metastatic cancer. IDC-G305 is an immunotherapy consisting of recombinant&#xD;
      NY-ESO-1 antigen and the adjuvant, GLA-SE. The goal is for IDC-G305 to stimulate the body's&#xD;
      immune system to fight the spread and growth of cancer for patients whose tumors include the&#xD;
      NY-ESO-1 protein. Patients with melanoma, ovarian, renal cell or non-small cell lung cancer&#xD;
      may be considered for the trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open label, multicenter, multiple ascending dose trial of IDC-G305&#xD;
      administered by intramuscular injection in a 3+3 sequential dose escalation design. IDC-G305&#xD;
      is an immunotherapy consisting of recombinant NY-ESO-1 antigen and the adjuvant, GLA-SE.&#xD;
      Patients with unresectable, relapsed or metastatic cancer but with low disease burden and&#xD;
      indolent disease course may be considered for the trial. Tumors must express the NY-ESO-1&#xD;
      gene signature and tumor types that will be studied are: melanoma, ovarian, sarcoma,non-small&#xD;
      cell lung and breast cancer.&#xD;
&#xD;
      Each of three dose level cohorts will be treated contingent upon absence of dose limiting&#xD;
      toxicity (DLT) and acceptable safety data for the preceding cohort. Initially, three patients&#xD;
      will be scheduled to receive IDC-G305 in each dose level cohort. Dose escalation will be&#xD;
      contingent upon the assessment of safety data obtained during the initial injections.&#xD;
&#xD;
      Patients will be evaluated at baseline and at regular intervals for safety and immune&#xD;
      response. Both cellular and humoral immunogenicity will be explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1, open label, multicenter ascending dose study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 1 year after last vaccination</time_frame>
    <description>To evaluate the safety and tolerability of multiple ascending doses of intramuscular (IM) IDC-G305</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Approximately 12 weeks</time_frame>
    <description>The secondary objective is to evaluate the humoral and cellular immunogenicity of multiple ascending doses of intramuscularly administered IDC-G305</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Melanoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IDC-G305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NY-ESO-1 recombinant protein together with GLA-SE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IDC-G305</intervention_name>
    <description>NY-ESO-1 recombinant protein together with GLA-SE</description>
    <arm_group_label>IDC-G305</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of melanoma, ovarian cancer, sarcoma, breast cancer or non-small&#xD;
             cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Unresectable, relapsed and/or metastatic cancer with minimal or low disease burden.&#xD;
             Disease may or may not be measurable and should not be rapidly progressive. Inadequate&#xD;
             response, relapse and/or unacceptable toxicity with one or more prior systemic,&#xD;
             surgical, or radiation cancer therapies, except patients with NSCLC and breast cancer&#xD;
             who must have experienced an inadequate response and/or unacceptable toxicity with two&#xD;
             or more prior systemic, surgical, or radiation cancer therapies.&#xD;
&#xD;
          -  Cancer expresses NY-ESO-1&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Life expectancy of ≥ 6 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  ECG without evidence of clinically significant arrhythmia or ischemia&#xD;
&#xD;
          -  Negative pregnancy test for females of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Vaccine or other therapy directed against NY-ESO-1 at any time in the past and any&#xD;
             investigational therapy within three weeks prior to IDC-G305 dosing&#xD;
&#xD;
          -  Significant immunosuppression&#xD;
&#xD;
          -  Cancer chemotherapy, G-CSF or GM-CSF within three weeks prior to the first study&#xD;
             treatment&#xD;
&#xD;
          -  Significant autoimmune disease&#xD;
&#xD;
          -  Myocardial infarction within six months of treatment, active cardiac ischemia or Grade&#xD;
             III or IV heart failure&#xD;
&#xD;
          -  Inadequate hematology or chemistry profiles&#xD;
&#xD;
          -  History of other cancer within three years&#xD;
&#xD;
          -  Active, concurrent or recent infection, including tuberculosis, hepatitis B, hepatitis&#xD;
             C or HIV&#xD;
&#xD;
          -  Uveal melanoma&#xD;
&#xD;
          -  Brain metastases considered unstable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunle Odunsi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

